Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 48

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

369

HTML

2409

Figures (1-1)

202

Tables (1-4)

210

Sum=3190

Dec 28, 2005 (publication date) through Nov 5, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Dec 28, 2005; 11(48): 7560-7563
Published online Dec 28, 2005. doi: 10.3748/wjg.v11.i48.7560

Table 2 Histological changes in liver biopsies

	Treated group (n = 14)		Untreated group (n = 9)
	Baseline	Post losartan	Baseline	Second biopsy
Histology activity index	8.08±2.56	8.54±1.51	7.0±2.12	7.6±2.3
Fibrosis stage	3.29±1.44	2.64±1.22	2.67±2	3.56±2.13
Sub-endothelial fibrosis (pixels/inch²)	2.48±1.04	1.00±0.53^a	1.65±0.43	1.55±0.27

Results are expressed as mean±SD.

^aP<0.01 vs baseline.

Citation: Sookoian S, Fernández MA, Castaño G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study. World J Gastroenterol 2005; 11(48): 7560-7563
URL: https://www.wjgnet.com/1007-9327/full/v11/i48/7560.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i48.7560